[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:b-acute-lymphoblastic-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":308,"states":321},"B Acute Lymphoblastic Leukemia",66,53,[8,16,23,29,36,42,48,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,169,175,181,187,193,198,205,211,217,223,229,235,241,247,253,259,264,269,275,280,286,292,298,303],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05480449","Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:58.452248Z","2026-07-05T05:32:16.805466Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04546399","A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)",[20],"Phase 2","2026-08-26T02:18:29.369233Z","2026-07-05T05:32:16.793102Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT02981628","Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",[20],"2026-08-03T00:52:47.662427Z","2026-07-05T05:32:16.771394Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT03150693","Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",[33],"Phase 3","2026-08-26T02:16:51.982021Z","2026-07-05T05:32:16.770812Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07223021","A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia",[33],"2026-08-26T02:16:47.762107Z","2026-07-05T05:32:16.665217Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07328503","CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:29.590010Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT07133997","Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia",[52],"Phase 1","2026-08-26T02:17:20.511551Z","2026-05-05T02:43:29.580504Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04746209","Blinatumomab After TCR Alpha Beta\u002FCD19 Depleted HCT",[20],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:29.539043Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT02877303","Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:29.482656Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07053059","Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",[20],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.369796Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06137118","AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia",[12],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:29.024177Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06124157","A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",[20],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.515234Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06559189","CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",[52],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.501492Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05010564","Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)",[52],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.287884Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04544592","UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",[12],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.281463Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06863259","Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL",[52],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.191020Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06317662","Testing the Addition of the Anti-cancer Drug Venetoclax and\u002For the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia",[20],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.976183Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06144606","Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.927667Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06287229","Phase Ib\u002FII Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed\u002FRefractory (R\u002FR) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab\u002FHCVAD-inotuzumab-blinatumomab",[12],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:27.836826Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05674175","Co-administration of CART22-65s and huCART19 for B-ALL",[12],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.600390Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT05645718","Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",[20],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.390966Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT07040982","Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[52],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.099677Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT03739814","Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.037393Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT04150497","Phase 1\u002F2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",[12],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:26.923457Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT06738368","Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:26.755408Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT03509961","The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL",[20],"2026-08-26T02:19:19.975067Z","2026-05-05T02:35:31.695914Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT04276870","Orphan Indications for CD19 Redirected Autologous T Cells",[20],"2026-08-26T02:15:44.309045Z","2026-05-05T02:35:31.686030Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT07224100","Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia\u002FLymphoma",[20],"2026-08-26T02:17:10.213717Z","2026-05-05T02:35:31.650647Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07109219","Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:17:21.315591Z","2026-04-29T02:57:57.110500Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT03959085","Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",[33],"2026-08-26T02:18:17.950264Z","2026-07-05T03:45:20.447682Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":89,"content_modified":197},"NCT03595917","ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",[52],"2026-05-05T02:43:29.224482Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":203,"content_modified":204},"NCT04512716","Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",[202],"Early Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:26.957051Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT06034275","Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies",[52],"2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.754345Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[12],"2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT04318678","CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",[52],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.730542Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[12],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[52],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.704804Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[12],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT06395103","Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A\u002FLIGHTBEAM-U01)",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.012234Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT01371630","Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.961680Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":59,"content_modified":263},"NCT03666000","Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)",[52],"2026-05-05T02:43:27.435593Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":113,"content_modified":268},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[12],"2026-05-05T02:43:27.324190Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06879340","Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies",[52],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.323625Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":185,"content_modified":279},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[52],"2026-05-05T02:35:31.644184Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT05281809","Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:19:03.581490Z","2026-04-29T02:57:57.140676Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT05621291","A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...",[],"2026-08-26T02:16:03.788292Z","2026-05-05T02:35:31.935053Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT07422337","A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL\u002FLy Who Have Received Blinatumomab",[],"2026-08-26T02:18:46.137046Z","2026-05-13T02:55:06.702451Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":284,"content_modified":302},"NCT07117136","Blinatumomab Consolidation in Real World",[],"2026-05-13T02:55:06.655533Z",{"nct_id":304,"title":305,"phases":306,"status":13,"updated_at":77,"content_modified":307},"NCT07048535","CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions",[],"2026-05-13T02:55:06.647956Z",[309,313,317],{"biomarker":310,"count":311,"slug":312},"CD19 Gene",24,"cd19-gene",{"biomarker":314,"count":315,"slug":316},"CD22 Gene",14,"cd22-gene",{"biomarker":318,"count":319,"slug":320},"BCR\u002FABL1 Fusion Gene",5,"bcr-abl1-fusion-gene",[322,326,330,334,337,341,345,349,352,355,358,361,364,367,371,374,377,381,384,387,391,394,397,401],{"state":323,"count":324,"slug":325},"Texas",31,"texas",{"state":327,"count":328,"slug":329},"California",22,"california",{"state":331,"count":332,"slug":333},"New York",20,"new-york",{"state":335,"count":332,"slug":336},"Pennsylvania","pennsylvania",{"state":338,"count":339,"slug":340},"Florida",18,"florida",{"state":342,"count":343,"slug":344},"Maryland",17,"maryland",{"state":346,"count":347,"slug":348},"Colorado",16,"colorado",{"state":350,"count":347,"slug":351},"Illinois","illinois",{"state":353,"count":347,"slug":354},"Ohio","ohio",{"state":356,"count":347,"slug":357},"Washington","washington",{"state":359,"count":315,"slug":360},"Massachusetts","massachusetts",{"state":362,"count":315,"slug":363},"North Carolina","north-carolina",{"state":365,"count":315,"slug":366},"Wisconsin","wisconsin",{"state":368,"count":369,"slug":370},"Georgia",13,"georgia",{"state":372,"count":369,"slug":373},"Michigan","michigan",{"state":375,"count":369,"slug":376},"Tennessee","tennessee",{"state":378,"count":379,"slug":380},"Alabama",11,"alabama",{"state":382,"count":379,"slug":383},"Minnesota","minnesota",{"state":385,"count":379,"slug":386},"Missouri","missouri",{"state":388,"count":389,"slug":390},"Arizona",10,"arizona",{"state":392,"count":389,"slug":393},"New Jersey","new-jersey",{"state":395,"count":389,"slug":396},"Oregon","oregon",{"state":398,"count":399,"slug":400},"Arkansas",9,"arkansas",{"state":402,"count":399,"slug":403},"Iowa","iowa"]